Background: Combinations of antidepressant duloxetine (at doses of 40–60 mg/day) and other antipsychotics are frequently used in clinical treatment; however, several fatal and nonfatal cases of duloxetine overdose have been documented. We experienced a patient who had taken an overdose of duloxetine (780 mg) in combination with other drugs in a suicide attempt.Case presentation: The patient was a 37-year-old man (body weight, 64 kg) with a history of gender identity disorder and depression. He intentionally took an overdose of duloxetine in combination with three other antipsychotic drugs (18 mg flunitrazepam, 850 mg quetiapine, and 1100 mg trazodone) and was emergently admitted to Kyoto Medical Center. The patient’s plasma concentration of duloxetine during ambulance transport was 57 ng/ml, and the level was still as high as 126 ng/mL at 32 h after administration. Duloxetine disappeared most slowly from plasma, in contrast to quetiapine, which was the fastest to clear among the four medicines determined in this patient. The observed concentrations of duloxetine in this overdose patient were generally within the 95% confidence intervals of the plasma concentration curves predicted using a physiologically based pharmacokinetic (PBPK) model.Conclusion: Even if more than 1 h (the generally recommended period) has passed after administration of duloxetine in such overdose cases, gastric lavage and/or administration of activated charcoal may be effective in clinical practice up to 6 h because of the typically slow elimination behavior illustrated by the PBPK model. Pharmacokinetic profiles visualized using PBPK modeling can inform treatment decisions in cases of drug overdose for medicines such as duloxetine in emergency clinical practice.
1 January 2016 in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Many medical treatments, which were invasive and used to be provided under hospitalization, have been recently performed in the outpatient center. A multidisciplinary approach to the medical care is also required to secure safe and effective pharmacotherapy of the outpatient; therefore, the cooperative care between the hospital and community pharmacy is necessary. In Kyoto University Hospital, a new protocol, which consisted of 8 agreements between our hospital and community pharmacies, was conducted from October 2013. In these agreements, there were concrete examples, which were unrequired inquiries about the prescription to doctors by telephone. In December 2014, the protocol was revised to add 7 agreements, which were also unnecessary inquiries in outpatient prescriptions. The number of prescription changes based on the protocol significantly increased from 13% in September 2014 to 21% in March 2015 of the total changes including those by the phone call in the corresponding periods. Although 20% of the changes in the prescriptions deviated from the protocol in September 2014, the protocol deviations decreased to 7% in March 2015. From July 2014 to June 2015, 829 outpatient prescriptions were changed based on the protocol, and a maximum of 10,940 yen per patient was saved, since the pharmacist found residual drugs in the patient's home and intervened to reduce medication days in the prescription. In conclusion, the protocol for unrequired inquiries about the prescription to doctors in the community pharmacy saved the working times of medical doctors and pharmacists, and possibly contributes to promoting pharmaceutical care to patients.
11 July 2023 in Journal of Infection and Chemotherapy